{
    "doi": "https://doi.org/10.1182/blood-2021-150649",
    "article_title": "Long-Term Subgroup Analyses from Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry ",
    "article_date": "November 5, 2021",
    "session_type": "615.Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies",
    "abstract_text": "INTRODUCTION The hypomethylating agents (HMAs), decitabine (DEC) and azacitidine (AZA), have made it possible to treat more elderly patients with acute myeloid leukemia (AML). Both HMAs have demonstrated efficacy in monotherapy and in combination with targeted therapies. However, there is little direct comparative data on AZA and DEC in first-line treatment, and we do not know which group of patients might benefit from each drug. Results of the full analysis set (FAS) were presented previously (Labrador J, et al. ASH 2020). Here, we report long-term clinical efficacy from prespecified patient subgroup analyses. METHODS We conducted a retrospective study to compare real-life clinical outcomes between AZA and DEC in patients with AML ineligible for intensive chemotherapy included in the PETHEMA registry, and analyzed clinical variables associated with response and overall survival (OS) between AZA and DEC. RESULTS A total of 626 patients were included for the FAS between 2006 and 2019. 487 (78%) received AZA and 139 (22%) received DEC. Baseline characteristics were comparable in both groups, except for the percentage of bone marrow blasts (44% vs. 34% in the DEC group compared to AZA, p=0.010). In the FAS, there was no difference in the CR, CR/CRi or ORR (CR/RCi + PR) rate: 18%, 20.5% and 32% with AZA vs. 23%, 25% and 39.5% with DEC (p=0.20, p=0.27 and p=0.12). In the subgroup analysis, DEC was associated with higher CR/CRi rate than AZA in patients with ECOG \u2265 2 (95% CI: 0.088 - 0.801), bone marrow blast count < 50% (95% CI: 0.293 - 0.965), secondary AML (95% CI: 0.223 - 0.918) and adverse cytogenetics (95% CI: 0.171 - 0.857) (Figure 1A). DEC was associated with higher ORR rate than AZA in patients with ECOG \u2265 2 (95% CI: 0.116 - 0.782), leukocytes < 10 x10 9 /L (95% CI: 0.321 - 0.920) and bone marrow blasts < 50% (95% CI: 0.321 - 0.920) (Figure 1B) 120 days-mortality was 25.4% after AZA and 27.1% after DEC, p=0.70. Patients who did not achieve at least a PR had significantly higher 120-day mortality with both HMAs (OR 8.85 and 8.22 for AZA and DEC, respectively). In the subgroup analysis, patients with leukocytes \u2265 10 x10 9 /L (95% CI: 1.069 - 4.157) and those with estimated glomerular filtration rate (eGFR) \u2265 45 mL/min/1.73m 2 (95% CI: 1.249 - 4.664) had higher 120-day mortality with DEC than with AZA (Figure 1C) With a median follow-up of 12 months, median OS was 10.4 months (95% CI: 9.2 - 11.7) for AZA vs. 8.8 months (95% CI: 6.7 - 11.0) for DEC (p = 0.455). The subgroup analysis revealed that patients \u2265 80 years (95%: CI 1.005 - 2.341), with leukocytes \u2265 10 x10 9 /L (95% CI 1.039 - 2.062), platelet count <20 x10 9 /L (95% CI: 1.150 - 3.422) and those with eGFR \u2265 45 mL/min/1.73m 2 (95% CI: 1.040 - 2.059) did benefit for treatment with AZA compared to DEC (Figure 1D). CONCLUSIONS Our study provides real-life data on the outcomes of AML patients treated with AZA compared to DEC in a large retrospective cohort with long-term follow-up. In addition, we identify for the first time some baseline characteristics that could benefit from AZA or DEC in terms of responses, 120-day mortality and OS. These findings could help us to choose the most appropriate HMA in monotherapy or for the development of new combinations. Figure 1 View large Download slide Figure 1 View large Download slide Close modal Disclosures de la Fuente:  Novartis: Research Funding; Abbie: Consultancy, Speakers Bureau; Incyte: Consultancy, Speakers Bureau; BMS: Consultancy, Speakers Bureau. Tormo:  Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Jazz Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. P\u00e9rez-Sim\u00f3n:  Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. Montesinos:  Forma Therapeutics: Consultancy; Tolero Pharmaceutical: Consultancy; Karyopharm: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Pfizer: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Sanofi: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Incyte: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Daiichi Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Glycomimetics: Consultancy; Agios: Consultancy; Stemline/Menarini: Consultancy; Teva: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; AbbVie: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Astellas Pharma, Inc.: Consultancy, Honoraria, Other: Advisory board, Research Funding, Speakers Bureau.",
    "author_names": [
        "Jorge Labrador",
        "Adolfo de la Fuente",
        "David Mart\u00ednez-Cuadr\u00f3n",
        "Rebeca Rodr\u00edguez-Veiga",
        "Josefina Serrano",
        "Mar Tormo",
        "Jose P\u00e9rez-Sim\u00f3n",
        "Fernando Ramos",
        "Teresa Bernal del Castillo",
        "Maria L\u00f3pez-Pav\u00eda",
        "Fernanda Trigo",
        "Pilar Martinez Sanchez",
        "Juan Ignacio Rodriguez-Gutierrez",
        "Carlos Rodriguez",
        "Cristina Gil",
        "Daniel Garcia",
        "Susana Vives",
        "Maria Angeles Foncillas",
        "Manuel Perez Encinas",
        "Andr\u00e9s Novo",
        "Isabel Recio",
        "Gabriela Rodriguez Macias",
        "Juan Miguel Bergua Burgues",
        "Victor Noriega Concepcion",
        "Esperanza Lavilla",
        "Alicia Rold\u00e1n P\u00e9rez",
        "Miguel A. Sanz",
        "Pau Montesinos"
    ],
    "author_dict_list": [
        {
            "author_name": "Jorge Labrador",
            "author_affiliations": [
                "Hematology Department, Research Unit, Hospital Universitario de Burgos, Burgos, Spain"
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Adolfo de la Fuente",
            "author_affiliations": [
                "MD Anderson Cancer Center Madrid, Madrid, Spain"
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "David Mart\u00ednez-Cuadr\u00f3n",
            "author_affiliations": [
                "Instituto de Investigaci\u00f3n Sanitaria La Fe (IISLAFE), Hospital Universitari i Polit\u00e8cnic La Fe, Valencia, Spain"
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Rebeca Rodr\u00edguez-Veiga",
            "author_affiliations": [
                "Hospital Universitari i Polit\u00e9cnic La Fe, Valencia, Spain"
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Josefina Serrano",
            "author_affiliations": [
                "IMIBIC, Hematology, Hospital Universitario Reina Sof\u00eda, UCO, C\u00f3rdoba, Spain"
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mar Tormo",
            "author_affiliations": [
                "Hematology Department, Hospital Cl\u00ednico Universitario-INCLIVA, Valencia, Spain"
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jose P\u00e9rez-Sim\u00f3n",
            "author_affiliations": [
                "Department of Hematology, University Hospital Virgen del Roc\u00edo, Instituto de Biomedicina de Sevilla (IBIS / CSIC / CIBERONC), Universidad de Sevilla, Sevilla, Spain"
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Fernando Ramos",
            "author_affiliations": [
                "Hematology Department, Hospital Universitario de Le\u00f3n, Le\u00f3n, Spain, Le\u00f3n, Spain"
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Teresa Bernal del Castillo",
            "author_affiliations": [
                "Instituto Universitario Oncol\u00f3gico e Instituto de Investigaci\u00f3n del Principado de Asturias (IUOPA, ISPA), Oviedo, ESP"
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Maria L\u00f3pez-Pav\u00eda",
            "author_affiliations": [
                "Hospital General Universitari de Val\u00e8ncia, Hematology Service, Valencia, Spain"
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Fernanda Trigo",
            "author_affiliations": [
                "Dept. of Clinical Hematology, Centro Hospitalar Universit\u00e1rio de S\u00e3o Jo\u00e3o, Porto, Portugal"
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Pilar Martinez Sanchez",
            "author_affiliations": [
                "Clinical Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain"
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Juan Ignacio Rodriguez-Gutierrez",
            "author_affiliations": [
                "Hospital Universitario Basurto, Bilbao, Spain"
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Carlos Rodriguez",
            "author_affiliations": [
                "Hospital Universitario de Gran Canaria Doctor Negr\u00edn, Las Palmas de Gran Canaria, Spain"
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Cristina Gil",
            "author_affiliations": [
                "Hematology Department, Hospital General Universitario de Alicante, Alicante, Spain"
            ],
            "author_rank": 15,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Daniel Garcia",
            "author_affiliations": [
                "Hematology Department, Hospital Sanitas La Zarzuela, Madrid, Spain"
            ],
            "author_rank": 16,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Susana Vives",
            "author_affiliations": [
                "ICO-Hospital Germans Trias i Pujol, Badalona, ESP"
            ],
            "author_rank": 17,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Maria Angeles Foncillas",
            "author_affiliations": [
                "Hospital Universitario Infanta Leonor, Madrid, Spain"
            ],
            "author_rank": 18,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Manuel Perez Encinas",
            "author_affiliations": [
                "Hospital Cl\u00ednico Universitario de Santiago de Compostela, Santiago de Compostela, Spain"
            ],
            "author_rank": 19,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Andr\u00e9s Novo",
            "author_affiliations": [
                "Hematology Department, Hospital Universitario Son Espases, Palma de Mallorca, Spain"
            ],
            "author_rank": 20,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Isabel Recio",
            "author_affiliations": [
                "Hematology Deparment, Complejo Asistencial de \u00c1vila, Avila, Spain"
            ],
            "author_rank": 21,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Gabriela Rodriguez Macias",
            "author_affiliations": [
                "Hematology and hemotherapy department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"
            ],
            "author_rank": 22,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Juan Miguel Bergua Burgues",
            "author_affiliations": [
                "Hematology, Hospital Universitario San Pedro de Alcantara. Caceres, C\u00e1ceres, ESP"
            ],
            "author_rank": 23,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Victor Noriega Concepcion",
            "author_affiliations": [
                "Hospital Universitario de A Coru\u00f1a, A Coru\u00f1A, ESP"
            ],
            "author_rank": 24,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Esperanza Lavilla",
            "author_affiliations": [
                "Hospital Universitario Lucus Augusti, Lugo, Spain"
            ],
            "author_rank": 25,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Alicia Rold\u00e1n P\u00e9rez",
            "author_affiliations": [
                "Hematology and hemotherapy department, Hospital Universitario Infanta Sof\u00eda, San Sebasti\u00e1n de los Reyes, Spain"
            ],
            "author_rank": 26,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Miguel A. Sanz",
            "author_affiliations": [
                "Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, Valencia, Spain"
            ],
            "author_rank": 27,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Pau Montesinos",
            "author_affiliations": [
                "Instituto de Investigaci\u00f3n Sanitaria La Fe (IISLAFE), Hospital Universitari i Polit\u00e8cnic La Fe, Valencia, Spain"
            ],
            "author_rank": 28,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-06-21T06:41:56",
    "is_scraped": "1"
}